{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:13:19Z","timestamp":1790723599179,"version":"4.1.0"},"reference-count":77,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Regular prophylaxis with factor VIII (FVIII) or FIX products to prevent bleeding in patients with severe hemophilia A (HA) and HB, respectively, results in marked suppression of the onset of arthropathy and contributes greatly to improvements in quality of life. Some issues remain with the use of clotting factor replacement therapy, however. The need for multiple IV infusions is associated with a substantial mental and physical burden, and the hemostatic effect of bypassing agents (BPAs) in patients with inhibitor is inconsistent. The development of subcutaneous products with prolonged hemostatic efficiency, irrespective of the presence of inhibitors, has been a longtime wish for patients. A new class of therapeutic agents that act by enhancing coagulation (emicizumab) and inhibiting anticoagulant pathways (fitusiran and concizumab) have been established, and clinical trials using these nonfactor products are ongoing. The current findings have demonstrated that prophylaxis by nonfactor products supports marked reductions of bleeding episodes in hemophilia patients with or without inhibitor. Emicizumab has already been approved for use internationally. Some concerns are evident, however. Thrombotic microangiopathy and thromboembolism have occurred in 5 emicizumab-treated patients receiving repeated infusions of activated prothrombin complex concentrates, and a sinus vein thrombosis has occurred in a fitusiran-treated patient receiving repeated infusions of FVIII product. Moreover, reliable techniques to monitor hemostatic function in patients receiving nonfactor products with concomitant BPA or FVIII\/FIX therapies require further assessment. These novel therapeutic agents have promising hemostatic properties, although wider experience in hemophilia centers is warranted to establish appropriate therapeutic strategies.<\/jats:p>","DOI":"10.1182\/blood-2018-07-820712","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T01:35:15Z","timestamp":1545096915000},"page":"399-406","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":76,"title":["New therapies using nonfactor products for patients with hemophilia and inhibitors"],"prefix":"10.1182","volume":"133","author":[{"given":"Keiji","family":"Nogami","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2020021109333922100_B1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"issue":"4","key":"2020021109333922100_B2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5435\/00124635-200407000-00004","article-title":"Hemophilic arthropathy","volume":"12","author":"Luck","year":"2004","journal-title":"J Am Acad Orthop Surg"},{"issue":"5","key":"2020021109333922100_B3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5581\/1516-8484.20130108","article-title":"Health-related quality of life in hemophilia: results of the Hemophilia-Specific Quality of Life Index (Haem-a-Qol) at a Brazilian blood center","volume":"35","author":"Ferreira","year":"2013","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"2","key":"2020021109333922100_B4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Haemophilia prophylaxis in Sweden","volume":"65","author":"Nilsson","year":"1976","journal-title":"Acta Paediatr Scand"},{"issue":"6","key":"2020021109333922100_B5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2020021109333922100_B6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020021109333922100_B7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"S 01 Suppl 1","key":"2020021109333922100_B8","first-page":"S29","article-title":"BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation","volume":"32","author":"Turecek","year":"2012","journal-title":"Hamostaseologie"},{"issue":"11","key":"2020021109333922100_B9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2012-01-407494","article-title":"A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models","volume":"121","author":"Stennicke","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2020021109333922100_B10","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"2020021109333922100_B11","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2020021109333922100_B12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/hae.13191","article-title":"Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials","volume":"23","author":"Tiede","year":"2017","journal-title":"Haemophilia"},{"issue":"8793","key":"2020021109333922100_B13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"issue":"6","key":"2020021109333922100_B14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1055\/s-0038-1648507","article-title":"Prevalence of inhibitors in a population of 3435 hemophilia patients in France","volume":"67","author":"Sultan","year":"1992","journal-title":"Thromb Haemost"},{"issue":"2","key":"2020021109333922100_B15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"18","key":"2020021109333922100_B16","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2020021109333922100_B17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hae.13050","article-title":"A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors","volume":"23","author":"Shinkoda","year":"2017","journal-title":"Haemophilia"},{"issue":"1","key":"2020021109333922100_B18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","article-title":"Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"5","key":"2020021109333922100_B19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-014-1572-4","article-title":"Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor","volume":"99","author":"Ogiwara","year":"2014","journal-title":"Int J Hematol"},{"issue":"11","key":"2020021109333922100_B20","first-page":"1186","article-title":"Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success","volume":"86","author":"Mariani","year":"2001","journal-title":"Haematologica"},{"issue":"1","key":"2020021109333922100_B21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0037-1612943","article-title":"The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"DiMichele","year":"2002","journal-title":"Thromb Haemost"},{"issue":"10 Suppl","key":"2020021109333922100_B22","first-page":"45","article-title":"The German Registry of immune tolerance treatment in hemophilia--1999 update","volume":"85","author":"Lenk","year":"2000","journal-title":"Haematologica"},{"issue":"11","key":"2020021109333922100_B23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","article-title":"Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors","volume":"7","author":"Coppola","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2020021109333922100_B24","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/hae.13531","article-title":"The Japanese Immune Tolerance Induction (J-ITI) study in haemophilia patients with inhibitor: Outcomes and successful predictors of ITI treatment","volume":"24","author":"Nogami","year":"2018","journal-title":"Haemophilia"},{"issue":"5","key":"2020021109333922100_B25","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2516.2009.02039.x","article-title":"Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)","volume":"15","author":"Chitlur","year":"2009","journal-title":"Haemophilia"},{"issue":"3","key":"2020021109333922100_B26","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V89.3.1115","article-title":"Nephrotic syndrome as a complication of immune tolerance in hemophilia B","volume":"89","author":"Ewenstein","year":"1997","journal-title":"Blood"},{"issue":"10","key":"2020021109333922100_B27","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"5","key":"2020021109333922100_B28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"issue":"24","key":"2020021109333922100_B29","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2020021109333922100_B30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2020021109333922100_B31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5482\/20170004","article-title":"Thromboembolic risks of non-factor replacement therapies in hemophilia","volume":"37","author":"Tiede","year":"2017","journal-title":"Hamostaseologie"},{"issue":"23","key":"2020021109333922100_B32","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020021109333922100_B33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2017-09-743385","article-title":"Novel therapeutics for hemophilia and other bleeding disorders","volume":"132","author":"Callaghan","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2020021109333922100_B34","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"2020021109333922100_B35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2020021109333922100_B36","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020021109333922100_B37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.tcam.2012.07.005","article-title":"New models of hemostasis","volume":"27","author":"McMichael","year":"2012","journal-title":"Top Companion Anim Med"},{"issue":"1","key":"2020021109333922100_B38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2008-1066024","article-title":"The phenotypic heterogeneity of severe hemophilia","volume":"34","author":"Jayandharan","year":"2008","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"2020021109333922100_B39","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1055\/s-0034-1395349","article-title":"Phenotypic heterogeneity of hemostasis in severe hemophilia","volume":"41","author":"Nogami","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2020021109333922100_B40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V88.4.1183.bloodjournal8841183","article-title":"Moderation of hemophilia A phenotype by the factor V R506Q mutation","volume":"88","author":"Nichols","year":"1996","journal-title":"Blood"},{"issue":"2","key":"2020021109333922100_B41","first-page":"305","article-title":"Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature","volume":"92","author":"van Dijk","year":"2004","journal-title":"Thromb Haemost"},{"issue":"3","key":"2020021109333922100_B42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0029-1222609","article-title":"Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia","volume":"35","author":"Franchini","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"2020021109333922100_B43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1160\/TH09-10-0732","article-title":"Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice","volume":"103","author":"Bolliger","year":"2010","journal-title":"Thromb Haemost"},{"issue":"6","key":"2020021109333922100_B44","doi-asserted-by":"crossref","first-page":"e38104","DOI":"10.1371\/journal.pone.0038104","article-title":"Modulation of mouse coagulation gene transcription following acute in vivo delivery of synthetic small interfering RNAs targeting HNF4\u03b1 and C\/EBP\u03b1","volume":"7","author":"Safdar","year":"2012","journal-title":"PLoS One"},{"issue":"21","key":"2020021109333922100_B45","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1182\/blood-2012-11-465674","article-title":"Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production","volume":"121","author":"Safdar","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2020021109333922100_B46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJMcibr1505657","article-title":"Targeting antithrombin to treat hemophilia","volume":"373","author":"Ragni","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2020021109333922100_B47","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-0037-1604053","article-title":"Emerging therapeutic strategies in the treatment of hemophilia A","volume":"43","author":"Muczynski","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"19","key":"2020021109333922100_B48","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","article-title":"Biology of tissue factor pathway inhibitor","volume":"123","author":"Wood","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020021109333922100_B49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.115.305996","article-title":"Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein","volume":"36","author":"Mast","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 1","key":"2020021109333922100_B50","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1111\/jth.12897","article-title":"New insights into the biology of tissue factor pathway inhibitor","volume":"13","author":"Maroney","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2020021109333922100_B51","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1073\/pnas.1119858109","article-title":"Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia","volume":"109","author":"Maroney","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"20","key":"2020021109333922100_B52","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1182\/blood-2010-10-311936","article-title":"Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor","volume":"117","author":"Waters","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2020021109333922100_B53","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/jth.12201","article-title":"Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein","volume":"11","author":"Waters","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2020021109333922100_B54","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1074\/jbc.M113.533836","article-title":"Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI)","volume":"289","author":"Dockal","year":"2014","journal-title":"J Biol Chem"},{"issue":"2","key":"2020021109333922100_B55","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood-2007-07-098913","article-title":"Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A","volume":"111","author":"Prasad","year":"2008","journal-title":"Blood"},{"issue":"Suppl 2","key":"2020021109333922100_B56","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.thromres.2012.02.030","article-title":"Hemostatic properties of a TFPI antibody","volume":"129","author":"Petersen","year":"2012","journal-title":"Thromb Res"},{"issue":"13","key":"2020021109333922100_B57","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2020021109333922100_B58","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"2020021109333922100_B59","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"},{"issue":"9","key":"2020021109333922100_B60","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A","volume":"57","author":"Yoneyama","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"2020021109333922100_B61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.V130.Suppl_1.85.85","article-title":"HAVEN 2 updated analysis: multicenter, open-label, Phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors [abstract]","volume":"130","author":"Young","year":"2017","journal-title":"Blood"},{"key":"2020021109333922100_B62","article-title":"Relative and absolute bioavailability study of emicizumab to bridge drug products and subcutaneous injection sites in healthy volunteers [published online ahead of print 19 September 2018]","author":"Kotani","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"2020021109333922100_B63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2020021109333922100_B64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"key":"2020021109333922100_B65","first-page":"ABSASY01.2","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: interim results from a phase 2 extension study in patients with hemophilia A or B with and without inhibitors","volume":"1","author":"Pasi","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"2020021109333922100_B66","unstructured":"World Federation of Hemophilia. Alnylam suspends fitusiran dosing due to thrombotic event in phase 2 open-label extension study. Available at: https:\/\/news.wfh.org\/alnylam-suspends-fitusiran-dosing-due-thrombotic-event-phase-2-open-label-extension-study\/. Accessed 6 March, 2018."},{"key":"2020021109333922100_B67","unstructured":"World Federation of Hemophilia. Update: FDA lifts suspension of fitusiran trial. Available at: https:\/\/news.wfh.org\/update-fda-lifts-suspension-fitusiran-trial\/. Accessed 6 March, 2018."},{"issue":"5","key":"2020021109333922100_B68","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2020021109333922100_B69","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2020021109333922100_B70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V130.Suppl_1.89.89","article-title":"Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2) [abstract]","volume":"130","author":"Kruse-Jarres","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021109333922100_B71","first-page":"2366","article-title":"Perioperative management on patients with hemophilia receiving fitusiran, an inventing RNAi therapeutic targeting antithrombin for the treatment of hemophilia [abstract]","volume":"130","author":"Negrier","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2020021109333922100_B72","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2020021109333922100_B73","first-page":"163","article-title":"Mode of enhancement in the global hemostatic potentials with concomitant use of bypassing agents and emicizumab in hemophilia A patients with inhibitor evaluated by ROTEM","volume":"1","author":"Yada","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"2020021109333922100_B74","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2020021109333922100_B75","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"issue":"8044","key":"2020021109333922100_B76","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder","volume":"2","author":"Brackmann","year":"1977","journal-title":"Lancet"},{"issue":"23","key":"2020021109333922100_B77","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/5\/399\/1552081\/blood820712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/5\/399\/1552081\/blood820712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T16:48:42Z","timestamp":1662655722000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/5\/399\/272778\/New-therapies-using-nonfactor-products-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,1,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-07-820712","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]}}}